Combination of IL-33 with PD-1 Blockade Augment mILC2s-Mediated Anti-Tumor Immunity

The proportion of group 2 innate lymphoid cells (ILC2s) originating from various tissue sources were quantified through flow cytometry, along with the determination of CD4+ T cell and CD8+ T cell percentages.